Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export.

Cell reports | 2019

Naproxen is a non-steroidal anti-inflammatory drug that has previously been shown to exert antiviral activity against influenza A virus by inhibiting nucleoprotein (NP) binding to RNA. Here, we show that naproxen is a potential broad, multi-mechanistic anti-influenza virus therapeutic, as it inhibits influenza B virus replication both in vivo and in vitro. The anti-influenza B virus activity of naproxen is more efficient than that of the commonly used neuraminidase inhibitor oseltamivir in mice. Furthermore, the NP of influenza B virus (BNP) has a higher binding affinity to naproxen than influenza A virus NP (ANP). Specifically, naproxen targets the NP at residues F209 (BNP) and Y148 (ANP). This interaction antagonizes the nuclear export of NP normally mediated by the host export protein CRM1. This study reveals a crucial mechanism of broad-spectrum anti-influenza virus activity of naproxen, suggesting that the existing drug naproxen may be used as an anti-influenza drug.

Pubmed ID: 31067470 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ATCC (tool)

RRID:SCR_001672

Global nonprofit biological resource center (BRC) and research organization that provides biological products, technical services and educational programs to private industry, government and academic organizations. Its mission is to acquire, authenticate, preserve, develop and distribute biological materials, information, technology, intellectual property and standards for the advancement and application of scientific knowledge. The primary purpose of ATCC is to use its resources and experience as a BRC to become the world leader in standard biological reference materials management, intellectual property resource management and translational research as applied to biomaterial development, standardization and certification. ATCC characterizes cell lines, bacteria, viruses, fungi and protozoa, as well as develops and evaluates assays and techniques for validating research resources and preserving and distributing biological materials to the public and private sector research communities.

View all literature mentions

GST (B-14) (antibody)

RRID:AB_627677

This monoclonal targets GST (B-14)

View all literature mentions

HSP 70 (3A3) (antibody)

RRID:AB_627759

This monoclonal targets HSP 70 (3A3)

View all literature mentions

Influenza A virus PB1 protein antibody (antibody)

RRID:AB_2753122

This polyclonal targets Influenza A virus PB1 protein

View all literature mentions

Influenza B M1 (1141) (antibody)

RRID:AB_629816

This monoclonal targets Influenza B M1 (1141)

View all literature mentions

Influenza A m1 (FluAc) (antibody)

RRID:AB_1124287

This monoclonal targets Influenza A m1 (FluAc)

View all literature mentions

Influenza B NP (1B6/B3) (antibody)

RRID:AB_1124295

This monoclonal targets Influenza B NP (1B6/B3)

View all literature mentions

Influenza A virus Nucleoprotein antibody (antibody)

RRID:AB_11168364

This polyclonal targets Influenza A virus Nucleoprotein

View all literature mentions

His-probe (AD1.1.10) (antibody)

RRID:AB_783791

This monoclonal targets His-probe (AD1.1.10)

View all literature mentions

Influenza A NP (9G8) (antibody)

RRID:AB_1124491

This monoclonal targets Influenza A NP (9G8)

View all literature mentions